Skip to content
Bored Studies
RecruitingPhase 1

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Autolus Limited · NCT07139743

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–60 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
24
US sites recruiting
1
Study start
August 4, 2025
Record last updated
October 16, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to at least 2 disease-modifying therapies.

Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion.

Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.

Being studied: Obecabtagene autoleucel (obe-cel)

Conditions: Progressive Multiple Sclerosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Willing and able to give written informed consent for participation in the study.
  • Ability and willingness to adhere to the protocol's Schedule of Activities and other requirements.
  • Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding.
  • Current diagnosis of PMS.
  • Must have been treated previously with at least 2 disease-modifying therapies.

Exclusion Criteria

  • Any medications prohibited by the protocol.
  • Highly active multiple sclerosis.
  • Diagnosis of another autoimmune central nervous system condition.
  • Active or uncontrolled fungal, bacterial, viral infection.
  • History of malignant neoplasms unless disease-free for at least 24 months.
  • History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant.

Recruiting US locations

  • Stanford University

    Palo Alto, CA 94304

    Site contact: neuroimmunologyresearch@stanford.edu

Study contacts (from the official record)

  • Autolus Ltd · +44 (0)203 911 4385 · clinicaltrials@autolus.com
All neurology studies in California →
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis (NCT07139743) | Bored Studies